Immunovant Posts 34% R&D Jump in Q1

Immunovant (NASDAQ:IMVT), a clinical-stage biotechnology company focused on therapies for autoimmune conditions, reported results for the quarter ended June 30, 2025, on August 11, 2025. Net loss per common share (GAAP) was $0.71 in Q1 FY2026. Research and development expenses rose sharply as the company continued pushing its lead anti-neonatal Fc receptor (FcRn) antibody, IMVT-1402, through six separate clinical trials. No revenue was reported as Immunovant remains pre-commercial. Overall, the period demonstrated increased spending to advance its pipeline. Source: Analyst estimates for the quarter provided by FactSet. Immunovant is advancing therapies that target autoimmune diseases, with its primary asset being IMVT-1402, an antibody designed to inhibit the neonatal Fc receptor. This approach aims to reduce the level of Immunoglobulin G (IgG), a type of antibody that can play a role in immune system attacks on the body’s own tissues. By lowering IgG, Immunovant targets underlying causes of conditions such as Graves’ disease and myasthenia gravis.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool